Q-omics provides the consensus-scored IL18BP profile across patient tissues and cancer cell-line models. IL18BP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL18BP is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IL18BP RNA expression shows 17,382 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where IL18BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL18BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL18BP survival associations across molecular data types. IL18BP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL18BP RNA expression–survival associations across cancer types. High IL18BP expression shows unfavorable associations in UVM, LGG and KIRP, but favorable associations in SKCM, CESC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL18BP RNA expression.
This table summarizes IL18BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IL18BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL18BP shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, HNSC, STAD and LIHC. The KIRC box plot shows higher IL18BP RNA expression in tumor versus normal tissue (log2 FC = +1.590, t-test p < 0.001).
This table shows molecular features associated with IL18BP in patient tissues and cancer cell lines. In patient samples, IL18BP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL18BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
